Tivicay (dolutegravir ) is an HIV treatment that belongs to the class of Integrase Inhibitors (InI's). Tivicay is approved in Australia for the treatment of HIV when taken in combination with other HIV treatments.
Tivicay is also approved by the U.S. Food and Drug Administration (FDA), and the regulatory authorities in Canada, Chile, and Europe, for the treatment of HIV-1 (correct at the time of writing).
|Also known as
||Available in doses suitable for children and/or young people.
|Availability in Australia
Available on the Pharmaceutical Benefits Scheme (PBS) through S100 prescribers since 2014
A Special Assistance Scheme (SAS) is in operation for this drug.This drug may be available through clinical trials in Australia.
||Tivicay comes in 50 mg tablets
Like most anti-HIV drugs, Dolutegravir must be taken in combination with other drugs to be completely effective. Commonly, Dolutegravir is combined with one other nucleoside (NRTI) drug and either a protease inhibitor or non-nucleoside, although other combinations are sometimes used. Your doctor will advise you on the right combination of drugs to suit your circumstances.
The usual dose of Tivicay is one 50 mg tablet once a day, morning or night with or without food.
People who have resistance to any of the other Integrase Inhibitors, the usual dose of Tivicay is one 50 mg tablet twice a day.
Your doctor will decide on the correct dose of Tivicay for you.
Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.
With or without food
Dolutegravir may be taken with or without food
All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.
Interactions with other drugs
For more information follow the above link to AIDSmeds.